Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 3/20 | 0.55 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 8/20 | 0.53 |
| ▸ | KIT | P10721 | 6/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | LCK | P06239 | 5/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | TEK | Q02763 | 3/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.50 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698050 | 0.81 | POLB (0.70) | DDR2KDRKITMAPK14LCK | |
| SCHEMBL4697842 | 0.76 | BRAF (0.64) | KDRKITTEKBRAFPOLB | |
| SCHEMBL14689711 | 0.76 | KDR (0.50) | KDRKITMAPK14LCKSRC | |
| SCHEMBL8886635 | 0.74 | CSF1R (0.70) | FLT3KDRBRAFCSF1R | |
| SCHEMBL4699073 | 0.74 | BRAF (0.60) | DDR2FLT3KDRKITMAPK14 | |
| SCHEMBL14572598 | 0.73 | LCK (0.57) | DDR2KITMAPK14LCKSRC | |
| SCHEMBL14110150 | 0.73 | MAPT (0.53) | KDRKITMAPK14LCKSRC | |
| SCHEMBL29515236 | 0.72 | LCK (0.77) | DDR2FLT3KDRKITMAPK14 | |
| SCHEMBL14953284 | 0.72 | LCK (0.77) | DDR2FLT3KDRKITMAPK14 | |
| SCHEMBL18874095 | 0.72 | BRAF (0.73) | KDRKITMAPK14LCKBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | HOLZER PHILIPP | 2008-11-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275054-A1 | 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors | EPHB3, EPHB2, EPHB1 | DDR2 632/4885FLT3 20/4885KDR 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.